On January 14, 2021, the National Institutes of Health COVID-19 Treatment Guidelines Panel revised its position on the off-label use of ivermectin to treat coronavirus disease 2019 (COVID-19) from “against” to “neither for nor against.” Ivermectin is approved by the U.S. Food and Drug Administration (FDA) for use in humans by prescription only as an oral treatment for some parasitic worms (intestinal strongyloidiasis and onchocerciasis) and as a topical to treat external parasites such as head lice and for skin conditions such as rosacea. The NIH panel recommendation of “neither for nor against” is the same . . .
News Report |